Skip to main content
NervGen Pharma Corp. logo

NervGen Pharma Corp. — Investor Relations & Filings

Ticker · NGEN ISIN · CA64082X2032 LEI · 549300CZ6Y0WSURPE203 TSXV Professional, scientific and technical activities
Open in API
Filings indexed 325 across all filing types
Latest filing 2021-08-19 Regulatory Filings
Country CA Canada
Listing TSXV NGEN

About NervGen Pharma Corp.

https://nervgen.com/

NervGen Pharma Corp. is a clinical-stage biotechnology company focused on the discovery and development of pharmaceutical treatments designed to promote nervous system repair following neurologic trauma and disease. The company's core mission is to enable the nervous system to repair itself, offering a pharmacologic approach to conditions previously considered irreparable. Its lead drug candidate is NVG-291, a novel therapy currently in Phase 1b/2a clinical trials (CONNECT SCI Study) for individuals living with chronic spinal cord injury (SCI). Recent study data has demonstrated durable improvements in function and quality of life in this patient population. NervGen is also advancing its next-generation candidate, NVG-300, into preclinical proof-of-concept studies for three initial indications, expanding its pipeline for nervous system disorders.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109FV2 Certification of Interim Filings for a venture issuer, signed by the CFO. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended June 30, 2021. The document is primarily an officer certification letter confirming the accuracy and completeness of the interim filings, without containing the actual financial data or substantive financial analysis itself. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report (IR) they reference. The document length is 3058 characters, which is relatively short and consistent with a certification letter rather than a full interim report. Therefore, the correct classification is Regulatory Filings (RNS).
2021-08-19 English
Interim financial statements/report – English.pdf
Regulatory Filings
2021-08-19 English
Report of exempt distribution excluding schedule 1 of Form 5.pdf
Regulatory Filings
2021-08-17 English
Material change report - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a Form 51-102F3 Material Change Report filed by NervGen Pharma Corp. It details a private placement financing transaction, including the number of units issued, pricing, warrants, and use of proceeds. The form is a regulatory filing used to disclose material changes to the company, specifically related to capital raising activities. The document length is 3434 characters, which is relatively short and focused on a specific event rather than a comprehensive financial report. It is not an annual or interim report, earnings release, or management discussion. It is not a proxy, AGM material, or legal proceeding. The content clearly relates to a financing event (private placement), which fits the category of Capital/Financing Update (CAP). Therefore, the appropriate classification is CAP with high confidence.
2021-08-09 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing a research collaboration between NervGen Pharma and Massachusetts General Hospital to study a compound for Alzheimer's disease. It contains no financial data, no regulatory form references, no voting results, no management changes, no earnings or financial statements, and no detailed investor presentation. It is a corporate announcement about a scientific collaboration and future clinical trials, typical of a general regulatory or corporate news announcement. The document length is about 10,941 characters, but it does not contain any financial or regulatory filing content. Therefore, it fits best under Regulatory Filings (RNS) as a general corporate announcement that does not fit other specific categories.
2021-08-09 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the grant of stock options to consultants. It details the number of options, exercise prices, vesting period, and compliance with exchange policies. There is no financial report, earnings data, or regulatory filing content. The document is an announcement related to stock options, which falls under capital or financing activities. Given the content and length, it is not a full report but an update on financing-related activity.
2021-07-17 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.